



10594994



```
chain nodes :
22 29 30 33
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 23 24
25 26 27 28
chain bonds :
1-13 2-29 6-22 11-20 15-25 29-30 29-33
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9 10-11 10-15 11-12 12-13 13-14
14-15 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26 26-27
27-28
exact/norm bonds :
1-2 1-5 1-13 2-3 2-29 3-4 6-22 10-11 10-15 11-12 11-20 12-13 13-14
14-15 15-25 16-17 16-21 17-18 18-19 19-20 20-21 23-24 23-28 24-25 25-26
26-27 27-28 29-30 29-33
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9
isolated ring systems :
containing 1 : 10 : 16 : 23 :
```

G1:CH,N

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
29:CLASS 30:CLASS 33:CLASS
```

EXR: Michael Barker


10594994

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 CH,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 15:51:37 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 163 TO ITERATE

100.0% PROCESSED 163 ITERATIONS

21 ANSWERS

SEARCH TIME: 00.00.01

L2 21 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

191.54

191.76

FILE 'CAPLUS' ENTERED AT 15:51:39 ON 16 FEB 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

EXR: Michael Barker

10594994

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Feb 2010 VOL 152 ISS 8
FILE LAST UPDATED: 15 Feb 2010 (20100215/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Dec 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Dec 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2

L3 5 L2

=> d ibib hitstr 1-5


EXR: Michael Barker

10594994

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2007:117627 CAPLUS
 DOCUMENT NUMBER: 147:440304
 TITLE: Treatment of prostate cancer, melanoma or hepatic cancer
 INVENTOR(S): Yaguchi, Shinichi; Koshimizu, Ichiro; Yoshimi, Hisashi; Matsuno, Toshiyuki; Watanabe, Tetsuo; Tsuchida, Yoshio; Saitoh, Kenichi
 PATENT ASSIGNEE(S): Zenyaku Kogyo Kabushiki Kaisha, Japan
 SOURCE: U.S. Pat. Appl. Publ., 8pp.
 CODEN: USXXGO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070244110	A1	20071018	US 2006-404078	20060414
PRIORITY APPLN. INFO.:			US 2006-404078	20060414


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 147:440304
 IT 685111-07-3P 866392-54-3P 866392-55-4P
 909300-06-7P 952481-20-8P 952481-21-9P
 952481-22-0P 952481-23-1P 952481-24-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (treatment of prostate cancer, melanoma or hepatic cancer)
 RN 685111-07-3 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)- (CA INDEX NAME)




RN 866392-54-3 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 952481-20-8 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(4,6-di-4-morpholinyl-1,3,5-triazin-2-yl)-4-methoxy- (CA INDEX NAME)



RN 952481-21-9 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.




RN 952481-22-0 CAPLUS

EXR: Michael Barker

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 866392-55-4 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 909300-06-7 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(3,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-, 4-acetate, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 952481-23-1 CAPLUS
 CN Carbonic acid, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-4-yl methyl ester (CA INDEX NAME)




RN 952481-24-2 CAPLUS
 CN Carbonic acid, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-1H-benzimidazol-4-yl ethyl ester, rel- (CA INDEX NAME)

Relative stereochemistry.

10594994

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
(immunosuppressive agents and anti-tumor agents comprising heterocyclic

compds.)

RN 475111-21-8 CAPLUS


CN 1H-Benzimidazol-4-ol,

2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (CA INDEX NAME)




RN 685111-07-3 CAPLUS

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (CA INDEX NAME)



RN 866392-55-4 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (CA INDEX NAME)



RN 866392-56-5 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-

EXR: Michael Barker

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:945639 CAPLUS

DOCUMENT NUMBER: 145:328368

TITLE: Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
Haruta, Kazuhiko; Yaguchi, Shinichi; Matsuno, Toshiyuki; Tsuchida, Yoshio; Watanabe, Tetsuo; Yoshioka, Kimitomo; Yui, Ryogo

PATENT ASSIGNEE(S): Zenyaku Kogyo Kabushikikaisha, Japan

SOURCE: PCT Int. Appl., 102pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006095906	A1	20060914	WO 2006-JP304937	20060313
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006221285	A1	20060914	AU 2006-221285	20060313
CA 2599879	A1	20060914	CA 2006-2599879	20060313
EP 1864665	A1	20071212	EP 2006-729002	20060313
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
BR 2006008291	A2	20091222	BR 2006-008291	20060313
US 20080113987	A1	20080515	US 2007-847593	20070830
IN 2007KN03220	A	20080104	IN 2007-KN03220	20070831
CN 101137382	A	20080305	CN 2006-80007888	20070911
KR 2007113285	A	20071128	KR 2007-723354	20071011
PRIORITY APPLN. INFO.:			JP 2005-69255	A 20050311

WO 2006-JP304937 W 20060313

WO 2006-JP4937 A1 20060313

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:328368

IT 475111-21-8P 685111-07-3P 866392-55-4P


866392-56-5P 866392-57-6P 866392-62-3P

909300-04-5P 909300-05-6P 909300-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 866392-57-6 CAPLUS

CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 866392-62-3 CAPLUS


CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (CA INDEX NAME)

10594994


L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 909300-04-5 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)



RN 909300-05-6 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)



L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1103774 CAPLUS
 DOCUMENT NUMBER: 143:367324
 TITLE: Preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivatives
 as antitumor agents
 INVENTOR(S): Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Saitoh, Kenichi;
 Watanabe, Tetsuo
 PATENT ASSIGNEE(S): Zenyaku Kogyo Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095389	A1	20051013	WO 2005-JP6111	20050330
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GM, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005227954	A1	20051013	AU 2005-227954	20050330
CA 2561406	A1	20051013	CA 2005-2561406	20050330
EP 1741714	A1	20070110	EP 2005-727794	20050330
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1972935	A	20070530	CN 2005-80010215	20050330
CN 100532380	C	20090826		
KR 2007008670	A	20070117	KR 2006-722675	20061030
US 20080287431	A1	20081120	US 2007-594944	20070117

PRIORITY APPLN. INFO.:

WO 2005-JP6111 W 20050330


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:367324
 IT 866392-54-3P 866392-55-4P 866392-56-5P
 866392-57-6P 866392-58-7P 866392-59-8P
 866392-60-1P 866392-61-2P 866392-62-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of 2-benzimidazolyl-4,6-dimorpholinylpyrimidine and 2-benzimidazolyl-4,6-dimorpholinyltriazine derivs. as antitumor


EXR: Michael Barker

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

RN 909300-06-7 CAPLUS
 CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(3,3-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]- (CA INDEX NAME)



IT 909300-31-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (immunosuppressive agents and anti-tumor agents comprising heterocyclic compds.)
 RN 909300-31-8 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,6-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (9 CITINGS)
 REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

agents)
 RN 866392-54-3 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 866392-55-4 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy- (CA INDEX NAME)




RN 866392-56-5 CAPLUS
 CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,3S)-2,3-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.


10594994

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 866392-57-6 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6R)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-2-pyrimidinyl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 866392-58-7 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-methoxy- (CA INDEX NAME)

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)




RN 866392-59-8 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-6-(4-morpholinyl)-1,3,5-triazin-2-yl]-4-methoxy-, rel- (CA INDEX NAME)

Relative stereochemistry.




RN 866392-60-1 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-4-methoxy-1-[4-(4-morpholinyl)-6-(2,2,5,5-tetramethyl-4-morpholinyl)-1,3,5-triazin-2-yl]- (CA INDEX NAME)


L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



RN 866392-61-2 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-(4,6-di-4-morpholinyl-2-pyrimidinyl)-4-ethoxy- (CA INDEX NAME)



RN 866392-62-3 CAPLUS
CN 1H-Benzimidazole, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-2-pyrimidinyl]-4-ethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS

EXR: Michael Barker

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RECORD
FORMAT

10594994

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN


ACCESSION NUMBER: 2004:370924 CAPLUS
DOCUMENT NUMBER: 140:375193
TITLE: Preparation of heterocyclic compounds and antitumor drugs containing the same as the active ingredient
INVENTOR(S): Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Tsuchida, Yoshio; Saito, Kenichi; Sasahara, Hiroya; Watanabe, Tetsuo
PATENT ASSIGNEE(S): Zenyaku Kogyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037812	A1	20040506	WO 2003-JP13589	20031024
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2503451	A1	20040506	CA 2003-2503451	20031024
AU 2003275630	A1	20040513	AU 2003-275630	20031024
EP 1557415	A1	20050727	EP 2003-758850	20031024
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1708495	A	20051214	CN 2003-80102030	20031024
CN 100402523	C	20080716		
US 200400440	A1	20060112	US 2003-532245	20050422
US 7153853	B2	20061226		
US 7153853	A1	20090605	HK 2006-106828	20060614
			JP 2002-311086	A 20021025
PRIORITY APPLN. INFO.:			WO 2003-JP13589	W 20031024

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:375193
IT 685111-07-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 2-(1-benzimidazolyl)-4-morpholino-1,3,5-triazine or -pyrimidine derivs. as antitumor drugs)
RN 685111-07-3 CAPLUS
CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(6-di-4-morpholinyl-1,3,5-triazin-2-yl)]- (CA INDEX NAME)

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2002:849619 CAPLUS
DOCUMENT NUMBER: 137:370113
TITLE: Preparation of heterocyclic compounds as antitumor agents
INVENTOR(S): Kawashima, Seiichiro; Matsuno, Toshiyuki; Yaguchi, Shinichi; Sasahara, Hiroya; Watanabe, Tetsuo
PATENT ASSIGNEE(S): Zenyaku Kogyo Kabushiki Kaisha, Japan
SOURCE: PCT Int. Appl., 39 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200208112	A1	20021107	WO 2002-JP4227	20020426
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2445395	A1	20021107	CA 2002-2445395	20020426
AU 2002253619	A1	20021111	AU 2002-253619	20020426
AU 2002253619	B2	20070517		
EP 1389617	A1	20040218	EP 2002-722829	20020426
EP 1389617	B1	20070103		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CN 1538967	A	20041020	CN 2002-812617	20020426
CN 1310907	C	20070418		
JP 3836436	B2	20061025	JP 2002-585412	20020426
AT 350376	T	20070115	AT 2002-722829	20020426
PT 1389617	E	20070430	PT 2002-722829	20020426
ES 2280530	T3	20070916	ES 2002-722829	20020426
US 20040116421	A1	20040617	US 2003-475094	20031024
US 7071189	B2	20060704		
US 20060247232	A1	20061102	US 2006-478647	20060703
US 7307077	B2	20071211		
PRIORITY APPLN. INFO.:			JP 2001-132250	A 20010427
			WO 2002-JP4227	W 20020426
			US 2003-475094	A1 20031027

OTHER SOURCE(S): MARPAT 137:370113
IT 475111-21-8P, 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholino-1,3,5-triazine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as antitumor agents)
RN 475111-21-8 CAPLUS

EXR: Michael Barker

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2010 ACS on STN (Continued)

CN 1H-Benzimidazol-4-ol, 2-(difluoromethyl)-1-[4-(2,2-dimethyl-4-morpholinyl)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT